Twist Bioscience, a San Francisco, CA-based company accelerating science and innovation through DNA synthesis, completed a $61m Series D financing.
Backers included ARCH Overage Fund, Merieux Developpement, Cormorant Asset Management, Fidelity Management and Research Company and Foresite Capital Management and additional investors ARCH Venture Partners, WuXi Healthcare Ventures, Illumina, Nick and Joby Pritzker (through their family’s firm Tao Invest), Paladin Capital Group, Yuri Milner, Boris Nikolic and additional strategic corporate and venture investors.
In addition, the company secured a debt facility of up to a $15m loan with an added $5m revolving account receivable line of credit through Silicon Valley Bank.
Founded in 2013 and led by Emily Leproust, Ph.D., CEO, Twist Bioscience has developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon, the company’s platform expedites the design, build, test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics, biodetection and data storage.
The company has raised a total of $133m, as well as $20m in debt.